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Background: Persistent immune activation and inflammation are lying behind HIV-infection even in the setting
of ART mediated viral suppression. The purpose of this study is to define the in vivo effect of two first-line ART
regimens on certain inflammatory mediators in male HIV patients.
Methods: Male, naive, HIV-infected volunteers were assigned either to tenofovir-DF/emtricitabine/efavirenz (Group_T)
or abacavir/lamivudine/efavirenz (Group_A). Platelet Activating Factor (PAF) levels and metabolic enzymes together
with HIV-implicated cytokines (IL-1beta, IL-6, IL-8, IL-10, IL-12p70, TNFa) and VEGF were determined for a 12-month
period. Differences within each group were determined by non-parametric Friedman and Wilcoxon test, while the
differences between the groups were checked by ANOVA repeated measures.
Results: Both ART regimens present pronounced effect on inflammatory mediators, resulting in decreased PAF levels
and Lipoprotein-associated phospholipase A2 (Lp-PLA2) activity for tenofovir-containing regimen and same as baseline
PAF levels with a peak though at the 3rd month as well as elevated Lp-PLA2 activity for abacavir-containing regimen.
Conclusions: Studies regarding the effect of first-line ART regimens on inflammation may be beneficial in preventing
chronic morbidities during HIV-treatment. From this point of view, the present study suggests an anti-inflammatory
effect of tenofovir-containing ART, while the temporary increase of PAF levels in abacavir-containing ART may be the
link between the reported cardiovascular risk and abacavir administration.
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The progress of ART over the years has turned HIV-
infection from lethal into a chronic disease. However,
immune activation and inflammation are lying behind
effectively treated patients causing various non-AIDS mor-
bidities as cardiovascular or renal diseases and cancers [1].
Consequently chronic HIV-associated inflammation is now
considered a significant factor for the above-mentioned
conditions while elevated inflammatory and coagulation
markers can predict higher morbidity and even mortality in
HIV infected population [2-4].* Correspondence: papakonstantinou.v@gmail.com
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article, unless otherwise stated.During HIV-infection specific cells of the immune sys-
tem become targets of the virus and secrete in response
several inflammatory factors as cytokines and chemo-
kines [5]. The effect of antiretrovirals on cytokines’ levels
seems contradictory. Abacavir is thought to be associ-
ated with increased cardiovascular risk as it up-regulates
pro-inflammatory cytokines and CRP [6,7]. Nevertheless,
its use was not always associated with increased levels of
inflammatory markers [8], showing a similar effect with
tenofovir-DF [9]. In addition both antiretrovirals had no
effect on coronary endothelial cell gene transcription
and protein expression of cytokines, supporting that the
increased cardiovascular risk is probably not through the
direct endothelial activation pathways [10]. The incon-
sistent effect of ART on cytokines’ levels maybe indi-
cates another inflammatory mediator to be responsibleed Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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cavir use.
Platelet Activating Factor (PAF) is one of the most po-
tent inflammatory factors and a significant signaling
molecule of the immune system, considered as a primi-
tive and universal cellular mediator [11,12] that partici-
pates in both physiological and pathological processes
[13,14]. Concerning PAF biosynthesis, there are two
distinctive pathways named de novo, responsible for the
constant PAF biosynthesis, and remodeling, activated as
a direct response to acute inflammatory processes [15],
with key-enzymes being dithiothreitol-insensitive PAF-
cholinephosphotransferase (PAF-CPT, EC 2.7.8.16) and
lyso-PAF:acetyl-CoA acetyltransferase (lyso-PAF-AT, EC
2.3.1.67) [16,17], respectively. PAF catabolism is moderated
by PAF-specific acetylhydrolase (PAF-AH, EC 3.1.1.47), and
its plasma isoform, Lipoprotein-associated phospholipase
A2 (Lp-PLA2) [18].
PAF is thought to be implicated in the progression of
HIV-infection as studies have revealed that HIV-infected
monocytes overexpress PAF through Tat protein [19,20].
It was found that altered host cells and their sub-
products as Tat protein induce PAF biosynthesis via
cytokines, as Tumor Necrosis Factor-alpha (TNFα), and
growth factors, as Vascular Endothelial Growth Factor
(VEGF) [21,22]. The produced PAF, as a secondary me-
diator, participates in several processes like monocyte
cell recruitment and increased vascular permeability,
which can lead to various morbidities [2,23,24]. A great
variety of antiretrovirals, backbone and HAART regi-
mens exhibit in vitro inhibitory effect against PAF activ-
ity [25] while many studies have underlined the need for
combined antiretroviral and anti-PAF action in drugs
like piperazine and its developed derivatives [26-28]. Pa-
tients with early or asymptomatic HIV-infection before
ART initiation have shown increased activity of PAF bio-
synthetic enzymes and Lp-PLA2 indicating a persistent
inflammatory condition [29]. It has also been proposed
that Lp-PLA2 could play the role of a sensitive marker
as its increased levels in HIV and AIDS patients may be
a physiological response protecting the host against PAF
or other oxidized phospholipids [30]. The implication of
PAF in HIV-infection is further supported by the benefi-
cial effect of PAF antagonists administration in animal
models for HIV-1 encephalitis [31,32] as well by the im-
provement of neuropsychological test scores in HIV-
patients under lexipafant, the first PAF antagonist used
in HIV-associated cognitive impairment [33].
The scope of this paper is to determine for the first
time the in vivo effect of two first line ART regimens on
PAF levels in HIV naive patients along with several
already established inflammatory biomarkers implicated
in HIV-infection. The hypothesis states that tenofovir-
DF/emtricitabine/efavirenz would down regulate PAFlevels in contrast to abacavir/lamivudine/efavirenz based
on preliminary data concerning the effect of the above
regimens on PAF enzymes [34,35].Methods
Study design
Study enrollment begun after obtaining approval from
the scientific board of the Red Cross General Hospital of
Athens in Greece and all volunteer patients have signed the
informed consent according to the Declaration of Helsinki.
The volunteers (n = 18) were recruited from the 3rd Internal
Medicine Department-Infectious Diseases Unit, Red Cross
General Hospital, Athens, Greece. All participants were
male, treatment naïve, and asymptomatic HIV-infected pa-
tients as determined by the presence of antibodies against
HIV measured by enzyme-linked immunosorbent assay
(ELISA) and confirmed by Western blot. All patients were
at CDC A2 clinical stage and fulfilled the criteria for ART
initiation according to the European [36] and International
guidelines [37]. The patients were assigned in 2 groups
at the discretion of the clinicians. Group_T (n = 8,
mean age = 46 ± 10 years, 50% smokers) received co-
formulated tenofovir-DF/emtricitabine with efavirenz
and Group_A (n = 10, mean age = 35 ± 11 years, 70%
smokers) received co-formulated abacavir/lamivudine
along with efavirenz. The exclusion criteria include in-
flammatory diseases (periodontal or autoimmune dis-
ease, other diseases (diabetes, hypertension), allergies
or any additional medication that may affect PAF
levels. The study lasted for 12 months and the blood
samples were collected before (baseline, defined as
0 months) and after 1, 3, 6, 9 and 12 months of treat-
ment initiation.Determination of PAF levels
The isolation and purification of PAF was according to
the method of Demopoulos et al. [38]. Briefly, 10 mL of
blood were collected from each human subject and
poured immediately into 40 mL of absolute ethanol. The
mixture was stirred and centrifuged at 300 × g for
10 min at room temperature. The supernatant and the
pellet were extracted separately according to the Bligh
and Dyer method [39] and the chloroform phase in each
case was stored at −20°C. The supernatant chloroform
extract contains PAF molecules that are loosely bounded
to plasma proteins and lipoproteins, named as free PAF,
while the pellet extract contains PAF molecules strongly
bounded to cellular structures, named as bound PAF.
The above extracts were purified on silicic acid column
chromatography that was eluted with 45 mL of metha-
nol/water (1:1.5, v/v), followed by 50 mL of methanol/
water (2:1, v/v). The initial 45 mL (containing the bulk
of proteinaceous and other non-lipid impurities) were
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purified by HPLC (Hewlett-Packard series 1100) on a
cation-exchange column. The solvent system consisted
of an isocratic elution of acetonitrile/methanol/water
(61:31:8, v/v/v) slightly modified from the one described
in the original paper [38]. The eluted substances were
detected using UV detection at 208 nm. The examined
samples were dissolved in BSA 1.25% in saline and its
PAF levels were measured by the aggregatory activity
(by a 400 VS aggregometer Chrono-Log, USA) towards
washed rabbit platelets. PAF levels are expressed as
fmol/mL of blood.
Isolation of plasma, platelets and leukocytes
The isolations of plasma, platelets (HPs) and leukocytes
(HLs) were carried out as previously described [40].
Briefly, human blood was collected from an antecubital
vein and distributed into a polyethylene tube containing
anticoagulant in a ratio of blood/anticoagulant: 9/1, in a
total volume of 10 mL. Each sample underwent multiple
centrifugations in order to isolate plasma, platelets and
leukocytes.
Enzymatic assays
Dithiothreitol-insensitive PAF-CPT and lyso-PAF-AT
activity assays were performed on the homogenates of
leukocytes and platelets. PAF-AH activity assays were
performed on the homogenates of leukocytes and plate-
lets as well as Lp-PLA2 activity assays on plasma as pre-
viously described [40]. The enzyme activity is expressed
as pmol/min/mg of total protein or pmol/min/μL of
plasma.
Biochemical markers and immunological analysis
Clinical biochemical markers were measured by a Siemens
Dimension RxL automatic analyzer. CD4 cell counts
were defined using Tetra One System on the EPICS XL
flow cytometer, while viral load was determined using
the Versant HIV-1 RNA 3.0 assay. Plasma levels of IL-
1β, IL-6, IL-8, IL-10, IL-12p70, TNFα and VEGF were
determined on a BD FACS Canto II Flow cytometer
using CBA flex set cytokine kit and data analysis was
performed by FCAP Array DIVA software. Cytokines
are expressed as pg/mL of plasma.
Statistical analysis
Normal distribution was checked by P-P graphs using
Shapiro-Wilk criterion. The results are expressed as me-
dian values and interquartile range (25th-75th). Differ-
ences within each group during the overall 12-month
treatment were determined by non-parametric Friedman
(displayed as ptime) analysis. Wilcoxon test was used to
compare the difference of specific time point with the
baseline values within each group (displayed as pspecific-time-point). After ranking the values, the differences
between the groups were checked by repeated measures
ANOVA and are displayed as Pintervention (Pint) for the
overall and Pspecific-time-point for each time point in
particular. Viral load changes are reported in a loga-
rithmic scale for convenience and not in order to
normalize the value. Statistical significance was con-
sidered as p < 0.05.
Results
Anthropometric and biochemical characteristics
Anthropometric and biochemical characteristics of patients
are shown in Additional file 1, presenting no difference
between the two groups (Pint.s > 0.05).
In both groups, viral load is progressively reduced dur-
ing the study period (ptime_A/T < 0.001), while CD4 cell
counts are gradually increased (ptime_A/T < 0.001) even
from the 1st month of treatment. White blood cell count
remains stable in both groups (ptime_T = 0.205, ptime_A =
0.091), belonging to the minimum level of the normal
range.
Despite the variations in the lipid profile of each group,
the values remain within the normal range. Particularly, in
both groups total cholesterol (ptime_T = 0.007, ptime_A =
0.001), LDL (ptime_T = 0.028, ptime_A = 0.007) and HDL
(ptime_T = 0.008, ptime_A = 0.002) are increased while triglyc-
erides remain stable (ptime_T = 0.170) in Group_T and are
increased in Group_A (ptime_A = 0.001).
Effect of ART regimens on PAF levels
Bound PAF levels in Group_T are differentiated through
the 12-month period (ptime_T = 0.010) and especially they
are decreased at the 1st, 3rd, 6th and 12th month (p1 =
0.008, p3 = 0.016, p6 = 0.039 and p12 = 0.008, respect-
ively). Bound PAF levels in Group_A are also differenti-
ated during the study period (ptime_A = 0.028), with a
single increase at the 3rd month (p3 = 0.016), (Table 1).
There is no overall differentiation between the groups
(Pint = 0.357), however a differentiation is achieved at the
3rd month (p3_A-T = 0.038) and a borderline one at the 12
th
month (p12_A-T = 0.083); (Figure 1).
Regarding Free PAF levels, in Group_T they are border-
line differentiated through the study period (ptime_T =
0.068) while in Group_A they remain stable throughout the
treatment period (ptime_A = 0.719), with no differentiation at
any time point for both groups nor between them (Pint =
0.917), (Additional file 2).
Effect of ART regimens on PAF basic biosynthetic enzymes
(PAF-CPT, lyso-PAF-AT) in leukocytes and platelets
As far as it concerns PAF biosynthesis in leukocytes,
the specific activity of PAF-CPT in Group_T is differ-
entiated during the 12-month period (ptime_T = 0.009)
with gradually reductions from the 1st to the 12th
Table 1 PAF levels and metabolic enzymes of ART groups
Parameter Groups Baseline/0 month 1st month 3rd month 6th month 9th month 12th month ptime Pint.
Bound PAF (fmol/mL)
T
1.66 1.11* 0.90* 1.08* 1.12 0.74*
0.010 0.357
(1.35-2.02) (0.70-1.18) (0.70-1.30) (0.70-1.54) (0.70-2.11) (0.70-1.18)
A
0.90 1.10 5.54* 1.42 1.14 1.53
0.028
P3 = 0.038
(0.70-6.20) (0.70-2.41) (0.97-17.29) (0.78-3.85) (0.93-1.71) (0.78-2.39) P12 = 0.083
PAF-CPT in HLs (pmol/min/mg)
T
546.50 336.00* 191.50* 232.00* 338.50* 288.50*
0.009
0.304
(416.50-730.25) (182.50-451.75) (114.50-518.00) (147.25-461.25) (231.25 -381.25) (236.50-341.75)
A
344.50 257.00 438.00 344.00 495.00 445.00*
0.085
(215.25-787.75) (221.75-515.25) (183.00-535.50) (173.50-795.50) (252.50-755.00) (330.00-920.00)
Lyso-PAF-AT in HLs (pmol/min/mg)
T
22.95 12.40 12.20 8.40* 13.85* 16.40*
0.002
0.818
(11.90-26.65) (10.75-33.27) (8.02-28.07) (2.22-12.92) (8.47-17.60) (9.77-19.75)
A
9.15 10.75 20.60* 10.55 13.50 12.50
0.141
(6.12-19.82) (5.25-22.20) (7.42-35.75) (6.85-27.27) (8.00-27.75) (6.50-24.25)
PAF-AH in HLs (pmol/min/mg)
T
69.17 55.68 70.71 54.18* 46.32* 45.81*
0.002
0.732
(42.94-106.97) (32.34-80.52) (37.47-114.14) (33.09-65.45) (28.23-62.67) (25.79-51.56)
A
50.54 52.68 64.03* 61.30 57.05 52.24
0.180
(46.57-58.78) (34.37-72.78) (50.80-92.62) (32.55-75.06) (36.49-66.05) (40.54-61.08)
Lp-PLA2 (pmol/min/μL)
T
29.35 26.15 34.20 29.10 26.40* 27.15*
0.003 0.017
(24.40-34.12) (23.70-35.37) (30.00-35.12) (26.15-38.47) (22.44-29.35) (20.79-28.50)
A
33.66 32.63 33.59 33.67 37.55* 33.33
0.002
P3 = 0.038
(30.30-35.89) (27.20-36.59) (29.32-38.15) (27.61-35.48) (35.67-42.43) (31.63-40.90) P12 = 0.083
Group_T: tenofovir-DF/emtricitabine/ efavirenz and Group_A: abacavir/lamivudine/ efavirenz. All the results are expressed as median values and interquartile range (25th-75th). HLs: Human Leukocytes. ptime displays the
difference within the group during the overall 12-month treatment.
*: displays the significant difference of each time point with the baseline value (p < 0.05).
Pint displays the difference between the two groups during the overall 12-month treatment.





















Figure 1 Comparison of Bound PAF levels between the ART groups, Group_T: tenofovir-DF/emtricitabine/efavirenz, Group_A:
abacavir/lamivudine/efavirenz, Data are expressed as median values and interquartile range (25th-75th). Pint. displays the overall
difference between the two groups. P displays the difference at a particular time point of the study occurred from the comparison of the two groups.
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and p12 = 0.008, respectively). In contrast, in Group_A
it is borderline differentiated through the study period
(ptime_A = 0.085), achieving however an increase, at the
12th month (p12 = 0.006). Although the comparison
of the two groups presents no overall differentiation
(Pint = 0.304), there is a significant one at the 12
th
month (p12_A-T = 0.016). Regarding the specific activ-
ity of lyso-PAF-AT, in Group_T it is differentiated
during the 12-month treatment (ptime_T = 0.002) with
significant decreases from the 6th to the 12th month
(p6 = 0.008, p9 = 0.008, p12 = 0.008, respectively). On
the contrary, in Group_A, no difference is observed
throughout the study period (ptime_A = 0.141), however,
an increase is detected at the 3rd month (p3 = 0.037);
(Table 1).
Regarding PAF biosynthesis in platelets, in Group_T the
specific activity of PAF-CPT remains stable through time
(ptime_T = 0.343) with a reduction, however, at the 12
th
month (p12 = 0.047). Besides, the specific activity of lyso-
PAF-AT in Group_T remains stable through the 12-
month period (ptime_T = 0.416), decreasing though at
the 9th month (p9 = 0.039), while in Group_A it is dif-
ferentiated during the study period (ptime_A = 0.041)
with a significant peak at the 3rd month of treatment
(p3 = 0.010); (Additional file 2).Effect of ART regimens on both catabolic isoforms of
PAF-acetylhydrolase: Lp-PLA2 in plasma and PAF-AH in
blood cells
The specific activity of Lp-PLA2 in plasma presents signifi-
cant variations throughout the study period in both ART
groups (ptime_T = 0.003 and ptime_A = 0.002); (Figure 2).
Specifically, in Group_T it is decreased at the 9th and 12th
month (p9,12 = 0.008), while in Group_A, it is increased at
the 9th month (p9 = 0.002), (Additional file 2).
Regarding the specific activity of PAF-AH in leuko-
cytes, in Group_T it is differentiated through the 12-
month period (ptime_T = 0.002), with significant decreases
from the 6th to the 12th month (p6 = 0.031, p9 = 0.016
and p12 = 0.008, respectively). In contrast, in Group_A,
the specific activity of PAF-AH is not differentiated dur-
ing the study period, achieving however a significant
peak at the 3rd month (p3 = 0.049), (Table 1).
Concerning the specific activity of PAF-AH in plate-
lets, only in Group_T it is differentiated through the
12-month period (ptime_T = 0.023), with significant reduc-
tions from the 6th to the 12th month (p6 = 0.016, p9 = 0.008
and p12 = 0.008, respectively), (Additional file 2).
In vivo effect of ART regimens on cytokines’ levels
Cytokines’ levels remain stable through the study period
in both groups (p’stime > 0.05), although a single increase
Figure 2 Comparison of Lp-PLA2 specific activity between the ART groups, Group_T: tenofovir-DF/emtricitabine/efavirenz, Group_A:
abacavir/lamivudine/efavirenz, Data are expressed as median values and interquartile range (25th-75th). Pint. displays the overall
difference between the two groups. P displays the difference at a particular time point of the study occurred from the comparison of the
two groups.
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the 1st month of treatment, (Additional file 3).
Discussion
Over the last 18 years, ART succeed in raising CD4 cell
counts and suppressing viral load which has remarkably
improved the course of HIV-disease, with longer survival
and improved quality of life [2]. At the same time, it has
led to the appearance of previously unrecognized
chronic complications, such as ischemic cardiovascular
events, cancer and nephropathy [41]. It is not clear yet
whether these manifestations are related to the ART ad-
ministration or the virus itself. Even patients under anti-
retroviral therapy with undetectable viral load present
long-term immune activation and chronic inflammation
[1,2]. Therefore the blocking of the above mechanisms
could be a parallel therapeutic approach. Although it has
been suggested that persistent inflammation is impli-
cated in chronic non-HIV related manifestations, it is
not clear yet which inflammatory mediators could be
used in clinical practice in order to reduce HIV morbid-
ity and mortality.
Our team has already shown that tenofovir-DF/emtri-
citabine/efavirenz has great in vitro inhibitory effect
against PAF [25] and decreases PAF biosynthesis duringa 6-month treatment period [34] while abacavir/lamivu-
dine/efavirenz has limited in vitro inhibitory effect [25]
against PAF and increases at the 3rd month lyso-PAF-
AT, which is implicated in acute inflammatory processes
[35]. The present study expands the previous data by
providing the effect of these ART regimens on PAF
levels during a 12-month period and the follow-up of
PAF metabolic enzymes’ activity at the 9th and 12th
month along with the levels of selected HIV-implicated
cytokines (IL-1β, IL-6, IL-8, IL-10, IL-12p70, TNFα and
VEGF).
In the present study, PAF levels in HIV patients are
measured for the first time, resulting surprisingly to
lower values than the average population although the
activity of PAF biosynthetic enzymes is much higher
[42]. One may suggest that a possible explanation may
be the increased activity of PAF catabolic enzyme,
namely PAF-AH for the cellular isoform and Lp-PLA2
for the plasma isoform, acting in order to counterbal-
ance PAF levels in blood. In addition, another possible
explanation for PAF decreased levels is the lower white
blood cell counts in HIV patients compared to healthy
population. The comparison of PAF levels between the
two groups reveals a significant increase in Group_A at
the 3rd month. This differentiation is probably attributed
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Group_A in parallel with the continual decrease of PAF
biosynthesis in Group_T. There is also a trend of differ-
ence at PAF levels noted at the 12th month, which may be
credited to the significant difference at the 12th month of
PAF-CPT as well to the opposite effect of the two regi-
mens on both biosynthetic enzymes. The above results of
higher PAF levels and metabolic enzymes’ activity, seen at
certain time points, support a possible direct effect of aba-
cavir than an indirect effect of immune reconstitution as
it occurs from the white blood cell count.
In this study the activity of Lp-PLA2, a well-known
cardiovascular risk marker and sensitive to PAF levels
[43], is higher than the average population [42]. Increased
PAF levels seem to increase Lp-PLA2 activity in order to
adjust PAF levels in blood and this may be the reason of
the significant overall differentiation of Lp-PLA2 activity
between the two groups spotted particularly at the 9th and
the 12th month. Moreover, in Group_T the decrease of Lp-
PLA2 at the 9th and the 12th month comes in accordance
with the decrease in PAF levels during the 12-month
period. In Group_A the increase of PAF levels at the 3rd
month may be the reason of Lp-PLA2 raise at the 9th
month or this raise possibly reflects a direct effect of abaca-
vir/lamivudine/efavirenz on this enzyme.
The inflammatory cytokines IL-1β, IL-6, IL-10, IL12p70
and TNFα are implicated both at the pathogenesis and the
morbidities of HIV infection. In the present study, cyto-
kines’ levels are higher than healthy population indicating
the immune state of these HIV patients [44]. Cytokines’
levels remain stable between and within ARTgroups during
the study period apart from an increase of TNFα levels at
the 1st month in Group_A. The elevated TNFα levels may
assist to the increased PAF levels at the 3rd month, knowing
that TNFα induces PAF biosynthesis and vice versa [45,46].Conclusion
In conclusion the present study points out the effect of
ART regimens to the persistent inflammatory state ob-
served in the setting of suppressive antiretroviral treatment.
The tested regimens caused an opposite outcome on PAF
levels and on Lp-PLA2 activity. Since PAF is a potent
inflammatory factor, associated with pro-atherosclerotic
complications, the above results indicate a potent anti-
inflammatory role for tenofovir based regimen while sug-
gest PAF as the missing link between the abacavir based
regiment and the reported cardiovascular risk.Study limitations
The main limitation of this research study is the number of
the samples. The reason is the chosen methods for PAF
which are quite strenuous and time consuming but also
more sensitive and trustful than other rapid methods.Female patients have not been used in the study as the
menstrual cycle affects the metabolism of PAF.
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